slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 222,541-222,570
Pages 10,126
Rows per page 30
Component
222,541-222,570 of 303,780
20
The slide uses a hierarchical tree structure to represent the balance sheet components.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
21
The slide uses two distinct waterfall diagrams to explain how Pathward secures its position in different financial products.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
22
Pathward Financial | Investor Presentation Deck | 23 slidesPathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
01
RayzeBio | IPO Presentation Deck | 41 slidesRayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
02
RayzeBio | IPO Presentation Deck | 41 slidesRayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
03
This is a standard IPO/follow-on offering summary table.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
04
The slide uses a structured table format to present key company metrics and status.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
05
RayzeBio | IPO Presentation Deck | 41 slidesRayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
06
The slide uses a Gantt-style visualization for drug development stages.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
07
Uses a visual metaphor of 'Outside in' vs 'Precise from within' to contrast the two treatment modalities.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
08
The slide uses a simple comparison framework to highlight clinical benefits.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
09
The slide uses a comparison framework to justify the use of alpha-emitting isotopes in targeted radiotherapy.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · Problem1 hit
10
The slide uses a chronological progression of therapeutic classes (Targeted, Immuno-oncology, ADCs, Cell Therapy) leading to RPT.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit
11
The slide uses a comparison table to validate the market potential of the radiopharmaceutical space by highlighting a competitor's success.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit
12
The slide uses a process flow diagram to show the standard of care progression for two types of NETs.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
13
The slide uses a Kaplan-Meier curve to contrast Lutathera against a control group, highlighting the clinical limitation of the current standard of care.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
14
The chart compares median progression vs median survival in months across three patient cohorts (Pancreatic, GI, Overall).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The slide uses a chemical structure comparison to illustrate the similarity in binder/chelator while highlighting the difference in radioisotope.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · Solution1 hit
16
The slide uses a process-oriented layout to show the transition between trial phases.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
17
The table specifically highlights that there were zero treatment-related serious adverse events (SAE) and zero discontinuations.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
18
Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
19
The chart tracks patient follow-up in weeks, with markers indicating dose, dose reduction, and clinical response (Partial Response, Progressive Disease, Stable Disease).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
20
RayzeBio | IPO Presentation Deck | 41 slidesRayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
21
The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Hypothesis Test1 hit
22
The slide uses a three-column layout to break down the market opportunity into patient population, pricing, and launch dynamics.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · Market Sizing1 hit
23
The slide highlights that 47% of SCLC samples show some level of SSTR2 expression, with 27% showing high expression.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
24
Includes a visual case study with PET scan images showing tumor reduction.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
25
The chart shows tumor growth over 57 days across four treatment groups, with the combination therapy (green line) demonstrating the most effective tumor suppression.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
26
The slide outlines a clinical trial protocol for a combination therapy involving RYZ101, chemotherapy, and PD-L1 inhibitors.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
27
Includes PET scan imagery and a pharmacokinetic tumor uptake graph comparing RAYZ-SSTR to DOTATATE.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit